A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.

Garon, E.B.; Cho, B.C.; Luft, A.; Alatorre-Alexander, J.; Geater, S.L.; Trukhin, D.; Kim, S.W.; Ursol, G.; Hussein, M.; Lim, F.L.; Yang, C.T.; Araujo, L.H.; Saito, H.; Reinmuth, N.; Kohlmann, M.; Lowery, C.; Mann, H.; Peters, S.; Mok, T.S.; Johnson, M.L.

doi:10.1016/j.cllc.2024.03.003

A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.

Détails

Télécharger: 38584069.pdf (2487.05 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0

ID Serval

serval:BIB_7A92BC1E6EB4

Type

Article: article d'un périodique ou d'un magazine.

Collection

Publications

Institution

UNIL/CHUV

Titre

A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.

Périodique

Clinical lung cancer

Auteur⸱e⸱s

Garon E.B., Cho B.C., Luft A., Alatorre-Alexander J., Geater S.L., Trukhin D., Kim S.W., Ursol G., Hussein M., Lim F.L., Yang C.T., Araujo L.H., Saito H., Reinmuth N., Kohlmann M., Lowery C., Mann H., Peters S., Mok T.S., Johnson M.L.

ISSN

1938-0690 (Electronic)

ISSN-L

1525-7304

Statut éditorial

Publié

Date de publication

05/2024

Peer-reviewed

Oui

Volume

25

Numéro

3

Pages

266-273.e5

Langue

anglais

Notes

Publication types: Journal Article ; Clinical Trial, Phase III
Publication Status: ppublish

Mots-clé

Humans, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/pathology, Lung Neoplasms/drug therapy, Lung Neoplasms/pathology, Antibodies, Monoclonal, Humanized/administration & dosage, Antibodies, Monoclonal, Humanized/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Antibodies, Monoclonal/administration & dosage, Antibodies, Monoclonal/therapeutic use, B7-H1 Antigen/metabolism, B7-H1 Antigen/antagonists & inhibitors, Male, Female, Treatment Outcome, Clinical trial, Cytotoxic T-lymphocyte-associated antigen 4, Immune checkpoint inhibitor, Immunotherapy, Programmed cell death ligand-1

URN

urn:nbn:ch:serval-BIB_7A92BC1E6EB44

OAI-PMH

oai:serval.unil.ch:BIB_7A92BC1E6EB4

DOI

10.1016/j.cllc.2024.03.003

Pubmed

38584069

Web of science

001244527100001

Open Access

Oui